The RheumNow Week in Review – 5 May 2017 Save
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
- Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response http://buff.ly/2qtWoc6
- Risk Factors for RA-ILD RA-ILD are age, male, Hi Dz, RF+, CCP+, Smoking (esp w/HLA-DRB1), occurs w/in 10yrs RA onset https://t.co/zTCEZieO1m
- FDA approved oral MTX soln(Xatmet) 2.5mg/ml for poly JIA. Much cheaper to drink parenteral MTX (2.5mg/ml) @same dose https://t.co/T0os9AW4KS
- ACPA positive Non-RA pts w/ ST elevation MI greater mortality (HR 3.1), re-infarction & death (HR 2.4) than ACPA neg https://t.co/vAd8WTMK4m
- Study of 94 pts shows magnesium oxide not significantly better than placebo in treating nocturnal leg cramps. https://t.co/7BgRTu9YRu
- PRAISE patients for: 1) Weight loss 2) stop Smoking 3) achieving numeric Remission 4) Birthdays (recent, upcoming) 5) big career/life events
- 99FM pts had MRI sacroiliitis 8% & met AxSpA criteria 10%. But no control group comparison? Can AS masquerade as FM? https://t.co/PkH4t3CKGh
- FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17 https://t.co/P5kQd2DZc1
- Early Arthritis study, 14% got RA; MRI tenosynovitis predictive (OR7.5) w/ NPV 95%, PPV 25%,moreso w/ oligoarthritis https://t.co/M0SYxNL2jL
- Enthesitis-Related Arthritis in Children
- Venous Thromboembolism Risk Factors in ANCA-Associated Vasculitis
- FDA Approves Abaloparatide (Tymlos) for High Risk Patients
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.